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Abstract 
Background. The TIMI-AF score was described to predict net clinical outcomes (NCOs) in 
atrial fibrillation (AF) patients receiving warfarin. However, this score derived from the 
ENGAGE AF-TIMI 48 trial, and no external validation exists in real world clinical practice. 
We tested the long-term predictive performance of the TIMI-AF score in comparison with 
CHA2DS2-VASc and HAS-BLED in a ‘real world’ cohort of anticoagulated AF patients. 
Methods. We included 1156 consecutive AF patients stable on vitamin K antagonist (INR 
2.0-3.0) during 6 months. The baseline risk of NCOs (composite of stroke, life-threatening 
bleeding, or all-cause mortality) was calculated using the novel TIMI-AF score. During 
follow-up, all NCOs were recorded and the predictive performance and clinical usefulness of 
TIMI-AF was compared with CHA2DS2-VASc and HAS-BLED.  
Results. During 6.5 years (IQR 4.3-7.9), there were 563 NCOs (7.49%/year). ‘Low’ risk 
(6.07%/year) and ‘medium’ risk (9.49%/year) patients defined by the TIMI-AF suffered more 
endpoints that ‘low’ and ‘medium’ risks patients of CHA2DS2-VASc and HAS-BLED 
(2.37%/year and 4.40%/year for ‘low’ risk; 3.48%/year and 6.39%/year for ‘medium’ risk, 
respectively). The predictive performance of TIMI-AF was not different from CHA2DS2-
VASc (0.678 vs. 0.677, p=0.963) or HAS-BLED (0.644 vs. 0.671, p=0.054). Discrimination 
and reclassification did not show improvement of prediction using the TIMI-AF score, and 
decision curves analysis did not demonstrate higher net benefit. 
Conclusions. In VKA-experienced AF patients, the TIMI-AF score has limited usefulness 
predicting NCOs over a long-term period of follow-up. This novel score was not superior to 
CHA2DS2-VASc and HAS-BLED identifying ‘low risk’ AF patients.  
Keywords: atrial fibrillation, anticoagulants, hemorrhage, stroke, mortality, risk prediction   
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Introduction 
Oral anticoagulation (OAC) in AF patients reduces the risk of stroke by 64% and the risk of 
all cause mortality by approximately 26% compared to control or placebo in trials 
1
, with 
similar beneficial outcomes seen in everyday clinical practice 
1-5
. For years, the Vitamin K 
Antagonists (VKAs, mainly warfarin and acenocoumarol) were the first option for OAC and 
thus, widely used worldwide.  
Since the emergence of the Non-Vitamin K antagonist Oral Anticoagulants (NOACs, 
dabigatran, rivaroxaban, apixaban, and edoxaban), the landscape of stroke prevention has 
changed, with increasing use of OAC in many countries 
6
. This is because the NOACs show 
relative efficacy, safety and convenience compared to VKA, without the need for routine 
anticoagulation monitoring 
7
, such that recent guidelines for the management of AF have 
recommend the use of NOACs over VKAs in patients newly initiating OAC (Class IA) 
8,9
. 
OAC use requires a balance between thromboembolic and bleeding outcomes, which 
have often been expressed in relation to the net clinical benefit of the treatment. Recently, the 
TIMI-AF score (3 points = age ≥75 and left ventricular ejection fraction <30%; 2 points = 
age 66-74, left ventricular ejection fraction 30-49%, hemoglobin <13 g/dL and non-white 
race; 1 point = unknown left ventricular ejection fraction, baseline AF or atrial flutter, prior 
ischaemic stroke, creatinine ≥110 umol/L, male sex, diabetes mellitus, carotid disease history 
and prior myocardial infarction) has been described to predict net clinical outcomes (the 
composite of disabling stroke, life-threatening bleeding, or all-cause mortality) in patients 
receiving warfarin therapy 
10
. This score was derived from the ENGAGE AF-TIMI 48 trial 
cohort and no external validation exists as yet. Composite scores for 
stroke/thromboembolism/bleeding prediction have previously been described, but such an 
approach combining risk factors into a new risk score for composite events did not perform 
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much better than the established CHA2DS2-VASc and HAS-BLED scores for stroke and 
bleeding risk prediction, respectively 
11
.  
In the present study, we tested the long-term predictive performance of the TIMI-AF 
score and performed a comparison with CHA2DS2-VASc and HAS-BLED scores in a ‘real 
world’ cohort of anticoagulated AF patients. 
 
 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
5 
Methods 
For the present study from the Murcia AF Project, we included consecutive patients with 
paroxysmal, persistent or permanent AF who during the previous 6 months were stable on 
vitamin K antagonist (VKA; INR 2.0-3.0). The recruitment was carried out in our single 
anticoagulation center in a tertiary hospital in Murcia (South-east Spain) during a period of 7 
months (from May 1, 2007 to December 1, 2007). At baseline, all patients were taking OAC 
with acenocoumarol (the commonest VKA used in Spain) and consistently achieved an INR 
between 2.0 and 3.0 during the previous 6 months (to ensure baseline homogeneity of the 
included cohort). We excluded patients with rheumatic mitral valves and prosthetic heart 
valves, as well as those with any acute coronary syndrome, stroke, hemodynamic instability, 
hospital admissions or surgical interventions in the preceding 6 months. 
At inclusion, a complete medical history was recorded. The time in therapeutic range 
(TTR) was calculated at 6 months after entry by the linear interpolation method of Rosendaal. 
Stroke risk and bleeding risk were assessed using the CHA2DS2-VASc and HAS-BLED 
scores 
12,13
. The risk of net clinical outcomes was calculated using the novel TIMI-AF score, 
giving 3 points to age ≥75 and left ventricular ejection fraction <30%; 2 points to age 66-74, 
left ventricular ejection fraction 30-49%, hemoglobin <13 g/dL and non-white race, and 1 
point to unknown left ventricular ejection fraction, baseline AF or atrial flutter, prior 
ischaemic stroke, creatinine ≥110 umol/L, male sex, diabetes mellitus, carotid disease history 
and prior myocardial infarction, as described by Fanola et al. 
10
 (Online Table 1). 
 
Study outcomes 
The primary endpoint for this study was net clinical outcome (composite of disabling stroke, 
life-threatening bleeding, or all-cause mortality). As secondary endpoints we analyzed 
ischaemic strokes, major bleeds and deaths. Ischaemic stroke and was defined as the sudden 
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onset of a focal neurological deficit in a location consistent with the territory of a major 
cerebral artery resulted of an obstruction documented by imaging, surgery or autopsy. Major 
bleeding was defined based on 2005 International Society on Thrombosis and Haemostasis 
(ISTH) criteria 
14
. The follow-up was performed by personal interview at each visit to the 
anticoagulation clinic and through medical records. The investigators had full access to 
patients’ clinical histories including Computed Tomography (CT) scan or Magnetic 
Resonance Imaging (MRI) and therefore identified, confirmed and recorded all adverse 
events. Last follow-up visit was carried out on January 26, 2016 and no patient was lost.  
The study protocol was performed in accordance with the ethical standards laid down in 
the 1964 Declaration of Helsinki and approved by the Ethics Committee from University 
Hospital Morales Meseguer. All patients gave informed consent to participation in the study. 
 
Statistical analysis 
Continuous variables were expressed as mean ± standard deviation (SD) or median and 
interquartile range (IQR) as appropriate, whilst categorical variables were expressed as 
absolute frequencies and percentages. The Pearson Chi-squared
 
test was used to compare 
proportions.  
Cox proportional hazard regression models were performed to determine the 
association between higher values of the TIMI-AF, CHA2DS2-VASc and HAS-BLED scores, 
and primary/secondary endpoints. Differences in event-free survival by the different risk 
categories of TIMI-AF, CHA2DS2-VASc and HAS-BLED were reflected by Kaplan-Meier 
curves.  
To evaluate the predictive ability (expressed as c-indexes) of the different risk scores, 
receiver operating characteristic (ROC) curves were applied. The methods of DeLong et al. 
were used for the ROC curves and ROC curves comparisons 
15
. Discrimination and 
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reclassification performances were evaluated by the integrated discrimination improvement 
(IDI) and the net reclassification improvement (NRI), as described by Pencina et al 
16
. The 
clinical usefulness and the net benefit of the risk scores were estimated using the decision 
curve analysis (DCA), according to the method proposed by Vickers et al 
17,18
.  
A p value <0.05 was accepted as statistically significant. Statistical analyses were 
performed using SPSS v. 19.0 (SPSS, Inc., Chicago, IL, USA), MedCalc v. 16.4.3 (MedCalc 
Software bvba, Ostend, Belgium) STATA v. 12.0 (Stata Corp., College Station, TX, USA) 
and survIDINRI package for R v. 3.3.1 for Windows. 
 
Sources of Funding 
This work was supported by Instituto de Salud Carlos III (ISCIII), Fondo Europeo de 
Desarrollo Regional (FEDER) (Research projects: PI13/00513 and P14/00253), Fundación 
Séneca (Grant number: 19245/PI/14) and Instituto Murciano de Investigación Biosanitaria 
(IMIB16/AP/01/06). José Miguel Rivera-Caravaca has received a grant from Sociedad 
Española de Trombosis y Hemostasia (Grant for short international training stays 2016). 
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Results 
 
Over a median follow-up of 6.5 years (IQR 4.3-7.9), 1156 patients (49.3% male; median age 
76, IQR 71-81 years), were followed-up. Baseline clinical characteristics are summarized in 
Table 1. At entry, median CHA2DS2-VASc and HAS-BLED scores were 4 (IQR 3-5) and 2 
(IQR 2-3), respectively. The median TIMI-AF score was 6 (IQR 4-7). Median TTR at 6 
months after entry was 80% (IQR 66-100). During follow-up, there were 97 (8.4%, 
1.30%/year) ischaemic strokes, 168 major bleeds (14.5%, 2.24%/year), and 470 deaths 
(40.7%, 6.25%/year). The net clinical outcomes endpoint was recorded in 563 patients 
(48.7%, 7.49%/year). 
 
Ischaemic stroke and bleeding 
In the analysis of the 97 ischaemic stroke events, 1% were categorized as ‘medium’ risk 
by the CHA2DS2-VASc (i.e. score=1) and 99% as ‘high’ risk patients (i.e. score ≥2); 
importantly no ‘low risk’ patients by CHA2DS2-VASc suffered a stroke. Using the TIMI-AF 
score, 56.7% of the ischaemic strokes occurred in ‘low risk’ patients (i.e. score 0-6), 33.0% 
occurred in ‘medium risk’ patients (score 7-9 points), and 10.3% in ‘high’ risk patients (score 
≥10). 
For bleeding events, 11.3% of major bleeds were in the ‘low risk’ patients according to 
the HAS-BLED score (score 0-1), whilst 29.2% of major bleeds were in the ‘medium risk’ 
category (score=2); however, the vast majority of bleeding events (59.5%) were sustained in 
‘high risk’ patients (score ≥3). Using the TIMI-AF score, 53.6% of major bleedings were 
sustained in ‘low risk’ patients, 37.5% in ‘medium risk’ patients, and 8.9% in ‘high risk’ 
patients.  
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Net clinical outcomes  
For the ‘net clinical outcomes’ endpoint, 0.4% were sustained by ‘low risk’ patients as 
defined by CHA2DS2-VASc and 8.2% as defined using HAS-BLED. More than half (51%) of 
the events were suffered by ‘low risk’ patients as defined using the TIMI-AF score. 
Corresponding figures for the ‘medium risk’ categories recorded 2.1% of events by 
CHA2DS2-VASc, 36.2% by HAS-BLED and 40.3% by TIMI-AF.  
Using CHA2DS2-VASc, the ‘high risk’ category, had 97.5% of the recorded outcomes, 
whilst the ‘high risk’ HAS-BLED and TIMI-AF categories accounted for 55.6% and 8.7% of 
the events, respectively (Table 2).  
 
Survival analyses 
Cox regression analyses demonstrated a relative risk of ischaemic stroke of 1.45 (95% CI 
1.28-1.64, p<0.001) for each CHA2DS2-VASc score point, 1.65 (95% CI 1.41-1.93, p<0.001) 
for HAS-BLED, and 1.23 (95% CI 1.12-1.35, p<0.001) for TIMI-AF. The risk of major 
bleeding per each score point was 1.18 (95% CI 1.07-1.30, p<0.001) for CHA2DS2-VASc, 
1.49 (95% CI 1.31-1.93, p<0.001) for HAS-BLED, and 1.23 (95% CI 1.12-1.35, p<0.001) for 
TIMI-AF. Finally, the risk of net clinical outcomes was 1.34 (95% CI 1.27-1.41, p<0.001) for 
CHA2DS2-VASc, 1.46 (95% CI 1.34-1.57, p<0.001) for HAS-BLED, and 1.25 (95% CI 1.20-
1.30, p<0.001) for TIMI-AF with each score point (Online Table 2).  
Figure 1 shows Kaplan-Meier survival analyses with the different risks of each 
category for, CHA2DS2-VASc and HAS-BLED and TIMI-AF scores. This analysis also 
demonstrates that both ‘low risk’ (annual rate 6.07%/year) and ‘medium risk’ (9.49%/year) 
patients defined by the TIMI-AF sustained more primary endpoints than the ‘low risk’ and 
‘medium risk’ category patients using CHA2DS2-VASc and HAS-BLED (annual rates of 
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2.37%/year and 4.40%/year for ‘low’ risk; 3.48%/year and 6.39%/year for ‘medium’ risk, 
respectively) (Table 2).  
 
Prediction of net clinical outcomes 
The TIMI-AF score demonstrated a modest predictive performance for net clinical outcomes, 
with a c-index of 0.677 (95% CI 0.649-0.704). The predictive performance of CHA2DS2-
VASc was similar (c-index = 0.678, 95% CI 0.650-0.705) and non-significantly different 
from the c-index of TIMI-AF (0.678 vs. 0.677, p=0.963). The HAS-BLED score showed a 
slight worse predictive performance, but also not significantly different from TIMI-AF (0.644 
vs. 0.677, p=0.054) (Figure 2).  
A summary of the ROC curve comparisons, as well as IDI, NRI and median 
improvement analyses are detailed in Table 3. Based on the IDI, the TIMI-AF score showed 
for net clinical outcomes a non-significant improvement of 1.2% (p=0.418) and 2.3% 
(p=0.119) against CHA2DS2-VASc and HAS-BLED, respectively. In the same way, the NRI 
showed a non-significant positive reclassification over CHA2DS2-VASc (0.5%, p=0.925) and 
HAS-BLED (10.5%, p=0.139) scores. The median improvement of the TIMI-AF score over 
CHA2DS2-VASc and HAS-BLED at 6.5 (IQR 4.3-7.9) years of follow-up was non-
significant (<0.1%, p=0.249 and 1.9%, p=0.090; respectively) (Table 3).  
In order to assess the clinical usefulness in real practice, we plotted DCAs which 
graphically demonstrated no net benefit of the TIMI-AF in comparison to the CHA2DS2-
VASc and HAS-BLED scores (Figure 3).  
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Discussion 
The principal finding of the present study investigating the predictive performance of the 
TIMI-AF score was that this novel score is not superior compared with the CHA2DS2-VASc 
and HAS-BLED scores to predict adverse net clinical outcome events in a ‘real world’ cohort 
of VKA-experienced AF patients who had stable INRs at inclusion. Second, the CHA2DS2-
VASc and HAS-BLED scores performed better in identifying ‘low risk’ patients. 
Consequently, our data suggest that the clinical usefulness of the TIMI-AF score in the ‘real 
world’ is limited.  
The TIMI-AF has been proposed to predict net clinical outcomes in AF patients taking 
OACs. This composite of events includes strokes, major bleeds, and all-cause deaths. 
Although this score could give physicians an overview of the risk of suffering an adverse 
clinical event of importance in AF patients, it will be difficult to reflect the individual risk of 
each event. For example, “high risk” patients according to the TIMI-AF score could have a 
higher risk of either disabling stroke, life-threatening bleeding or death. However, it cannot 
show if the risk of stroke is higher than the risk of bleeding or on the contrary, if the risk of 
bleeding is higher than the risk of stroke. Clinical decision-making could be quite different 
depending on if patients have a high risk of stroke or high risk of bleeding. Indeed, previous 
studies demonstrated that thromboembolic and bleeding risk classifications are correlated but 
not exchangeable and thus, the advantage of a strategy combining risk assessment is 
questionable 
19
.  
Predictors of adverse events incorporated in the TIMI-AF score are well known to be 
associated with stroke and major bleeding, and most are already included in the widely used 
CHA2DS2-VASc and HAS-BLED scores 
12,13
. This is the case of age, hemoglobin (as a way 
to assess anemia), history of previous stroke, renal function, sex, diabetes mellitus or history 
of coronary disease. Surprisingly, hypertension, a demonstrated risk factor of stroke and 
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bleeding in AF has not been included in this novel score. Indeed, hypertension is strongly 
related with AF and in the original article of TIMI-AF, hypertension was the commonest 
comorbidity, present in >90% of patients. In fact, the intimate association between 
hypertension, stroke and bleeding in AF is well known 
20-23
. 
One of the main advantages of CHA2DS2-VASc and HAS-BLED compared with the 
TIMI-AF is the prediction of low risk patients, even for net clinical outcomes. An issue of 
special interest is to define what annual rate of events we might assume to categorize patients 
as low risk. Using the CHA2DS2-VASc score, low risk patients (i.e. score 0 in males, 1 in 
females) generally have a stroke risk of <1%/year 
24-26
. In the same line, low risk (score 0-1) 
using HAS-BLED also have a risk of major bleeding, of <1%/year 
27
. In the original article of 
Fanola et al. the TIMI-AF ‘low risk’ patients had an annual event rate 3-fold higher (3.53%) 
10
. In our study, low risk patients categorized by the TIMI-AF score had a high event rate for 
net clinical outcomes of 6.07%/year, which was higher than the rates observed with low risk 
patients of CHA2DS2-VASc and HAS-BLED (2.37%/year and 4.40%/year, respectively).  
Importantly, the TIMI-AF was also described to aid selection of the type of oral 
anticoagulation treatment. According to this score, high risk (score ≥10) and intermediate risk 
(score 7-9) patients should be preferably treated with edoxaban, while low risk patients (score 
0-6) should be treated with either warfarin or NOACs. To date, there are no head-to-head 
trials demonstrating the superiority of a NOAC against others, so there is no evidence 
supporting the use of edoxaban in particular in high-medium risk patients. Additionally, our 
study showed that low risk patients categorized by the TIMI-AF score had an appreciable 
annual event rate, and are not ‘truly low risk’; hence, warfarin might still not be the optimal 
OAC treatment for them 
28-30
.  
How do trial cohorts translate to real world practice? The TIMI-AF score was 
developed using the data from AF patients from the ENGAGE AF-TIMI 48 trial. AF patients 
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in ‘real world’ clinical practice tend to be older, with many associated comorbidities and 
polypharmacy, and variable treatment adherence and follow-up, whereas in clinical trials, 
patients are often carefully selected with specific inclusion/exclusion criteria and carefully 
followed up in a protocol-based manner 
31,32
. Usually, AF patients in clinical trials undergo 
various procedures and follow-up appointments by protocol, which is uncommon in the real 
world. This is exemplified by (eg.) the inclusion of carotid disease or the percentage of left 
ventricular ejection function in the final model of the TIMI-AF score. However, an 
echocardiogram is not needed for routine risk assessment and therefore not necessary for 
OAC selection 
9
. Awaiting additional tests or multiple biomarker assays simply to define 
high(er) risk can delay the onset of OAC initiation, particularly in the first weeks of diagnosis 
when the risk is higher 
33
. 
 
Limitations 
This study is limited by its single centre design and the recruitment of a Caucasian based 
population. At baseline, all patients were stable with VKA (all INR the 6 months previous at 
entry between 2 and 3) to ensure baseline homogeneity. For the same reason patients with 
rheumatic mitral valves, prosthetic heart valves, acute coronary syndrome, stroke, 
hemodynamic instability, hospital admissions or surgical interventions in the preceding 6 
months were not included. Thus, these strict selection criteria may not reflect ‘typical’ 
clinical practice, but the long follow-up and the standard care received make our cohort 
suitable to test our hypotheses. Our dataset was collected in a prospective manner, but the 
statistical analyses presented in this study have been performed retrospectively. Of note, 
participant patients were carefully followed-up and all events (even very early ones) were 
recorded.  
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The TIMI-AF score was derived from the ENGAGE AF-TIMI 48 trial, a trial 
comparing outcomes in patients receiving VKA versus edoxaban. In the present study we 
only included patients receiving VKA, and thus we only investigated the role of the TIMI-AF 
score as risk prediction tool, but not as prediction scheme for choosing between NOAC and 
VKA.  
 
Conclusions 
In VKA-experienced AF patients with stable INR at study entry, the TIMI-AF score has 
limited usefulness to predict net clinical outcomes over a long-term period of follow-up. This 
novel score was not superior to CHA2DS2-VASc and HAS-BLED for identifying ‘low risk’ 
AF patients.  
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Figure legends 
Figure 1. Kaplan-Meier analysis for net clinical outcomes according to the risk categories of 
each score. 
Dashed lines = TIMI-AF; Solid lines = CHA2DS2-VASc; Crossed lines = HAS-BLED 
Green lines = Low Risk; Purple lines = Medium Risk; Orange lines = High Risk 
TIMI-AF categories were defined as low risk (score = 0-6), medium risk (score = 7-9), and 
high risk (score ≥10). CHA2DS2-VASc categories were defined as low risk (score = 0), 
medium risk (score = 1), and high risk (score ≥2). HAS-BLED categories were defined as 
low risk (score = 0-1), medium risk (score = 2) and high risk (score ≥3). 
Figure 2. ROC curves comparison for net clinical outcomes 
Figure 3. Decision curves for the TIMI-AF, CHA2DS2-VASc and HAS-BLED scores. 
This analysis shows the clinical usefulness of each score based on a continuum of potential 
thresholds for net clinical outcomes (x-axis) and the net benefit of using the model to stratify 
patients at risk (y-axis) relative to assuming that no patient will have a net clinical outcome. 
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Table 1. Baseline clinical characteristics. 
 TIMI-AF score  CHA2DS2-VASc score HAS-BLED score 
 Low risk Medium Risk High risk Low risk Medium risk High risk Low risk Medium Risk High risk 
N = 1156 N = 727 N = 368 N = 61 N = 13 N = 52 N = 1091 N = 161 N = 491 N = 504 
 
Male sex, n (%) 350 (48.1) 180 (48.9) 40 (65.5) 13 (100) 48 (92.3) 508 (46.6) 93 (57.8) 219 (44.6) 258 (51.2) 
Age (years), median (IQR) 74 (68-79) 79 (75-83) 80 (77-84.5) 58 (53-63.5) 63 (57.3-68) 77 (72-81) 64 (59-77) 76 (71-81) 78 (73-82) 
 
Comorbidities, n (%) 
Hypertension 598 (82.3) 313 (85.1) 52 (85.2) 0 (0.0) 22 (42.3) 941 (86.3) 51 (31.7) 435 (88.6) 477 (94.6) 
Diabetes mellitus 136 (18.7) 141 (38.3) 38 (62.3) 0 (0.0) 2 (3.8) 313 (28.7) 31 (19.3) 116 (23.6) 168 (33.3) 
Heart failure 105 (14.4) 210 (57.1) 55 (90.2) 0 (0.0) 2 (3.8) 368 (33.7) 40 (24.8) 150 (30.5) 180 (35.7) 
Prior stroke/TIA 98 (13.5) 103 (28.0) 24 (39.3) 0 (0.0) 0 (0.0) 225 (20.6) 5 (3.1) 26 (5.3) 194 (38.5) 
Renal impairment 43 (5.9) 62 (16.8) 23 (37.7) 1 (7.7) 3 (5.8) 124 (11.4) 2 (1.2) 8 (1.6) 118 (23.4) 
Prior myocardial infarction 93 (12.8) 97 (26.4) 38 (62.3) 0 (0.0) 3 (5.8) 225 (20.6) 27 (16.8) 62 (12.6) 139 (27.6) 
Current smoking habit 103 (14.2) 58 (15.8) 16 (26.2) 5 (38.5) 6 (11.5) 166 (15.2) 24 (14.9) 62 (12.6) 91 (18.1) 
Concomitant antiplatelet 
treatment 
93 (12.8) 90 (24.5) 24 (39.3) 1 (7.7) 6 (11.5) 200 (18.3) 5 (3.1) 18 (3.7) 184 (36.5) 
TTR at 6 month (%), median (IQR) 80 (66-100) 80 (61.3-100) 71 (57-83) 80 (73-85) 80 (60-100) 80 (66-100) 80 (80-100) 80 (66-100) 68 (50-83) 
TTR <65% at 6 month, n (%) 168 (23.1) 95 (25.8) 19 (31.1) 2 (15.4) 15 (28.8) 265 (24.3) 7 (4.3) 71 (14.5) 204 (40.5) 
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IQR = interquartile range; TIA = transient ischemic attack; TTR = time in therapeutic range. 
CHA2DS2-VASc = cardiac failure or dysfunction, hypertension, age ≥75 [doubled], diabetes, stroke [doubled] – vascular disease, age 65-74 years and sex category [female]; 
HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly age. 
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Table 2. Distribution of net clinical outcomes according to risk categories of each score. 
 TIMI-AF score CHA2DS2-VASc score HAS-BLED score 
Risk categories N (%) annual rate (%/year) N (%) annual rate (%/year) N (%) annual rate (%/year) 
Net Clinical Outcomes (N = 563) 
 
Low Risk 287 (51.0) 6.07 2 (0.4) 2.37 46 (8.2) 4.40 
Medium Risk 227 (40.3) 9.49 12 (2.1) 3.48 204 (36.2) 6.39 
High Risk 49 (8.7) 12.36 549 (97.5) 7.75 313 (55.6) 9.55 
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Table 3. ROC curves comparison, IDI, NRI and median improvement of the TIMI-AF score in comparison with CHA2DS2-VASc and HAS-
BLED scores for prediction of net clinical outcomes.  
 C-index 95% CI p z statistic
*
 p
*
 IDI p NRI p Median improvement p 
vs. TIMI-AF score 
       
CHA2DS2-VASc  0.678  0.650-0.705 <0.001 0.046 0.963 0.012 0.418 0.005 0.925 <0.001 0.249 
HAS-BLED  0.644  0.615-0.671 <0.001 1.925 0.054 0.023 0.119 0.105 0.139 0.019 0.090 
       
CI = confidence interval; IDI = integrated discriminatory improvement; NRI = net reclassification improvement. *for c-index comparison.  
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Figure 1. Kaplan-Meier analysis for net clinical outcomes according to the risk categories of each score.
Dashed lines = TIMI-AF; Solid lines = CHA2DS2-VASc; Crossed lines = HAS-BLED 
Green lines = Low Risk; Purple lines = Medium Risk; Orange lines = High Risk 
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TIMI-AF categories were defined as low risk (score = 0-6), medium risk (score = 7-9), and high risk (score ≥10). CHA2DS2-VASc categories 
were defined as low risk (score = 0), medium risk (score = 1), and high risk (score ≥2). HAS-BLED categories were defined as low risk (score = 
0-1), medium risk (score = 2) and high risk (score ≥3). 
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Figure 2. ROC curves comparison for net clinical outcomes 
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Figure 3. Decision curves for the TIMI-AF, CHA2DS2-VASc and HAS-BLED scores. 
This analysis shows the clinical usefulness of each score based on a continuum of potential thresholds for net clinical outcomes (x-axis) and the 
net benefit of using the model to stratify patients at risk (y-axis) relative to assuming that no patient will have a net clinical outcome. 
